{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-084175","form_type":"8-K","ticker":"NEUP","cik":"0001191070","company_name":"Neuphoria Therapeutics Inc.","filed_at":"2024-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.867453+00:00","generated_at":"2026-05-30T22:07:22.579847+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bionomics to re-domicile from Australia to US via scheme of arrangement with Neuphoria","bullets":["Holders receive 1 Neuphoria share per 1,440 ordinary shares or per 8 ADSs; estimated post-domicile Nasdaq price ~$3.50.","Board unanimously recommends approval; shareholder vote expected late Nov 2024, implementation early Dec 2024.","Re-domicile driven by loss of foreign private issuer status, reduced compliance costs, and greater US investor access.","No material change to assets, management, operations, or strategy expected; structure designed to be tax-neutral."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-084175","json":"https://secwatch.observer/filing/0001213900-24-084175.json","markdown":"https://secwatch.observer/filing/0001213900-24-084175.md","text":"https://secwatch.observer/filing/0001213900-24-084175.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024084175/0001213900-24-084175-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1191070/000121390024084175/ea0216237-8k_bionomic.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T22:07:22.579847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}